@article{f58b55e930bb408a940b779cacbaeb34,
title = "CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.",
author = "Han, \{Tae H.\} and Gopal, \{Ajay K.\} and Radhakrishnan Ramchandren and Andre Goy and Robert Chen and Matous, \{Jeffrey V.\} and Maureen Cooper and Grove, \{Laurie E.\} and Alley, \{Stephen C.\} and Lynch, \{Carmel M.\} and O'Connor, \{Owen A.\}",
note = "Brentuximab vedotin is an antibody-drug conjugate (ADC) that selectively delivers monomethyl auristatin E (MMAE) into CD30-expressing cells. This study evaluated the CYP3A-mediated drug-drug interaction potential of brentuximab vedotin and the excretion of MMAE. Two 21-day cycles of brentuximab vedotin (1.2 or 1.8 mg/kg intravenously) were administered to 56 patients with CD30-positive hematologic malignancies.",
year = "2013",
month = aug,
day = "1",
doi = "10.1002/JCPH.116",
language = "American English",
volume = "53",
journal = "The Journal of Clinical Pharmacology",
number = "8",
}